46.5 F
New York
Friday, December 4, 2020

Tiziana [NASDAQ: TLSA] Submits Patent Application For Use Of Foralumab In COVID-19

Must read

Ring [NYSEMKT: REI] Energy Started Drilling Operation In New Horizontal Well

Ring Energy declared that the company has started operations on its new well. The company told that in ten months, it finally initiated...

KKR [NYSE: KKR] Purchased Two Industrial Properties Of Worth $171Million

KKR & Co. Inc. announced that it purchased two properties in texas for distribution purposes. The industrial properties total an area of...

EchoStar [NASDAQ: SATS] Partners With JT And Brings A Single Terminal For Network Connectivity To Market

EchoStar Corp.  declared that it has collaborated with Jersey Telecom so that it can provide its clients in the United Kingdom and Europe...

Capstone [NASDAQ: CPST] Receives An 800Kw Microturbine Order From Costa

Capstone Turbine Corp. declared that it has acquired an order of 800KW microturbine from the Costa Group. The request was obtained by the...

Tiziana Life Sciences PLC [NASDAQ: TLSA] disclosed today it has submitted an application for the use of Foralumab in the treatment of COVID-19. The combination of anti-viral & anti-inflammatory drugs proven to be very useful in the treatment of COVID-19 patients at different stages, recent clinical studies suggested.

Foralumab is known as NI-0401 is a fully-human monoclonal anti-CD3 antibody which is developed for the treatment of autoimmune & inflammatory diseases.

Foralumab nasal administration has the potential to improve the immune system. It also has the ability to put down the cytokines storm and decrease respiratory failure in COVID-19 patients. Foralumab nasal administration when combined with other anti-viral drugs plays an important role in improving treatment efficacy.

Shares of Tiziana soared 19.06% at $12.37 during the trading of Thursday. It had trading volume of 1.6 million as compared to the average volume of 305.68K. Tiziana has total market capitalization of 411.70 million.

In the past 52-weeks of trading, this company’s stocks have fluctuated between the low of $1.54 and a high of $12.61. It has moved up 703.25% from 52-weeks low and moved down -1.90% from its 52-weeks high.

A biotechnology company has a worldwide license for the nasal administration of Foralumab and other anti CD3 mAbs for the treatment of various diseases. Earlier, Tiziana has developed the nasal spray device using Foralumab. The firm has also disclosed the successful completion Phase 1 trial with the oral administration of Foralumab.

More articles

Latest article

Vodafone [NASDAQ: VOD] and RingCentral signs a partnership to provide next-generation services

Vodafone signed a strategic alliance with Ring Central . The association will modify business connections and alliances. The enterprises have joined hands to...

Salesforce [NYSE: CRM] Enters A Deal To Acquire Slack

Salesforce engages in a contract to buy Slack at a worth of $27.7B. This purchase to build an operating system for the...

Xilinx [NASDAQ: XLNX] Announced That It Acquired Falcon Computing

Xilinx Inc. declared that it has purchased falcon Computing Solutions to make flexible computing more accessible and easily adapted by computer programmers. The...

Luokung Corp. [NASDAQ: LKCO] To Acquire EMG For RMB 836 Million

Luokung Technologies Corp. a location-based service company has agreed to buy EMG technologies for Ren Min Bi  836 million. The company will pay...

Nokia [NYSE: NOK] Extends Collaboration With AT&T to Deliver Seamless IoT Connectivity

Nokia Corp. declared that the company has extended its contract with AT&T . The collaboration among the companies can supply and provide an...

Wendy [NASDAQ: WEN] Strikes A Deal With Rebel Foods To Open 250 Cloud Kitchens.

Wendy’s Co. and Rebel foods have partnered to open about 250 cloud kitchens in India. These kitchens will only serve the customer with...

Tesla [NASDAQ: TSLA] Recalls 9537 SUV’s Because Of Manufacturing Issues

Tesla Inc. has released safety recall orders for more than 9500 of its vehicle in the United States. The vehicles include Model Xs...

Northrop [NYSE:NOC] awarded a deal of $4.8B for Global Hawk Aircraft

Northrop Gruman Corp. has been awarded a deal to perform development, transformation, retrofit, and sustenance activities for the Global Hawk Program. This deal...